Neuronetics announced EHR integration and Neuronetics stock fell 3.06 percent

Published on 10/08/2026 at 20:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Five brokers rate Neuronetics Moderate Buy at USD 4.67. Neuronetics stock costs EUR 1.90 on October 8, 2026 after EUR 1.96.

Key points in brief

Neuronetics announced a TrakStar integration with AdvancedMD on September 8, 2026.
The integration connects NeuroStar TMS workflows with an electronic health record system serving more than 65,000 practitioners.
Neuronetics stock was at EUR 1.90 at Lang & Schwarz on October 8, 2026, versus a EUR 1.96 prior close.
Five brokerages held a Moderate Buy consensus with an average USD 4.67 target, according to MarketBeat.

STIM, US64131A1051, Illustration mit AI erstellt.

Neuronetics stock was trading at EUR 1.90 at Lang & Schwarz on October 8, 2026, down 3.06 percent from the EUR 1.96 prior close. The company had announced a TrakStar integration with AdvancedMD on September 8, 2026, connecting its TMS practice platform with an electronic health record system.

Integration reaches 65,000 practitioners

According to Neuronetics on September 8, 2026, AdvancedMD serves more than 65,000 practitioners across 13,000 independent practices. The integration is designed to move treatment data into clinical, scheduling, billing and revenue-cycle workflows.

The rollout was planned for the fourth quarter of 2026 for NeuroStar providers already using AdvancedMD and for new AdvancedMD adopters. That gives the announcement a measurable operational angle: the potential customer base is defined by 13,000 practices rather than by a broad technology claim.

What does the integration change?

The chronology shows a company pairing platform expansion with still-negative earnings. On August 4, 2026, Neuronetics and investor Jorey Chernett outlined an understanding covering strategic, operational and financial options, as reported by Simply Wall St. On August 11, 2026, quarterly revenue reached USD 41.57 million, versus USD 40.17 million expected, while earnings per share showed a USD 0.05 loss, compared with a USD 0.12 consensus loss, according to MarketBeat. On September 8, 2026, the AdvancedMD integration became the latest dated operating milestone.

The next financial signal is the earnings comparison itself. Revenue exceeded the cited estimate by 3.49 percent, calculated from USD 41.57 million against USD 40.17 million, while the USD 0.05 loss was narrower than the USD 0.12 consensus loss by USD 0.07.

Analysts see a higher valuation

MarketBeat reported on October 6, 2026 that five brokerages held a Moderate Buy consensus, with four buy ratings and one sell rating. The average 12-month target was USD 4.67, while BTIG Research had a USD 6.00 target and B. Riley Financial had initiated coverage with a USD 5.00 target, according to the same MarketBeat report.

At Lang & Schwarz, the stock was trading at EUR 1.90 on October 8, 2026, down 3.06 percent versus the EUR 1.96 prior close. The reference quote was in the after-hours phase; the primary listing is Nasdaq under ticker STIM, and the finance profile classifies Neuronetics as a healthcare medical-device company. The further course of trading is shown by the continuously updated real-time quote of Neuronetics stock.